Seikagaku Launches HyLink, an Intra-Articular Single-Injection Viscosupplement for the Treatment of Knee Osteoarthritis in Italy
Corporate Report 2018
Ono and Seikagaku Announce the Topline Results from Phase III Confirmatory Study of ONO-5704/SI-613 in Patients with Knee Osteoarthritis in Japan
Consolidated Financial Results for the Thrid Quarter of Fiscal year 2018
Seikagaku will announce the financial results for the Third Quarter of the Fiscal Year ending March 31, 2019 at 15:00 on February 5, 2019.